Vollständiger Abstract
Worum geht es in dieser Arbeit?
ABSTRACT This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first‐line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Tomomi Yokozawa, Sayako Nakagawa, Yukio Suzuki, Aya Tokinaga‐Uchiyama, Katsuyuki Konnai, Hiroto Narimatsu, Yukihiko Hiroshima, Haruya Saji
- Quelle
- Clinical Case Reports
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 2050-0904, 2050-0904
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Tomomi Yokozawa, Sayako Nakagawa, Yukio Suzuki, Aya Tokinaga‐Uchiyama, Katsuyuki Konnai, Hiroto Narimatsu, Yukihiko Hiroshima, Haruya Saji (2026). Clinical Benefit of Pembrolizumab in Lynch Syndrome‐Associated Advanced Ovarian Cancer With Germline MSH6 Variant: A Case Report. Clinical Case Reports. https://doi.org/10.1002/ccr3.73444
Kontext